Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:20 PM
Ignite Modification Date:
2025-12-24 @ 9:20 PM
NCT ID:
NCT03066804
Eligibility Criteria:
Inclusion Criteria:
* Left ventricular ejection fraction (LVEF) \>40% by echo within 6 months prior to study entry or during the screening epoch
* Symptom(s) of heart failure (HF) requiring treatment with diuretics (including loop, or thiazide diuretics, or mineralocorticoid antagonist \[MRAs\]) for at least 30 days prior to study entry
* NYHA class II-IV
* Structural heart disease (left atrial enlargement or left ventricular hypertrophy) documented by echocardiogram.
* NT-proBNP \> 220 pg/mL for patients with no atrial fibrillation/atrial flutter (AF) or \>600 pg/mL for patients with AF
* KCCQ clinical summary score \< 75
* Patients on ACEi or ARB therapy must have a history of HTN
Exclusion Criteria:
* Any prior measurement of LVEF ≤ 40%, under stable conditions
* Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months , or urgent percutaneous coronary intervention (PCI) within 3 months or an elective PCI within 30 days prior to study entry
* Any clinical event within the 6 months prior to Visit 1 that could have reduced the LVEF (eg MI, coronary artery bypass graft \[CABG\]), unless an echo measurement was performed after the event confirming the LVEF to be \>40%
* Current (within 30 days from Visit 1) acute decompensated HF requiring therapy.
* Current (within 30 days from Visit 1) use of renin inhibitor(s), dual RAS blockade or LCZ696
* History of hypersensitivity to LCZ696 or its components
* Patients with a known history of angioedema
* Walk distance primarily limited by non-cardiac comorbid conditions at study entry
* Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, hemoglobin (Hgb) \<10 g/dL males and \< 9.5 g/dL females, or body mass index (BMI) \> 40 kg/m\^2.
* Systolic blood pressure (SBP) ≥ 180 mmHg at study entry, or SBP \>150 mmHg and \<180 mmHg at study entry unless the patient is receiving 3 or more antihypertensive drugs, or SBP \< 110 mmHg at study entry.
* Patients with HbA1c \> 7.5% not treated for diabetes
* Patients with prior major organ transplant or intent to transplant (ie on transplant list)
* eGFR \< 30 ml/min/1.73 m\^2 as measured by MDRD at screening
* Serum potassium \> 5.2 mmol /L (or equivalent plasma potassium value) at study entry
* History or presence of any other disease with a life expectancy of \< 3 years
* Pregnant or nursing women or women of child-bearing potential unless they are using highly effective methods of contraception
Other protocol-defined inclusion/exclusion criteria may apply.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
45 Years
Study:
NCT03066804
Study Brief:
Protocol Section:
NCT03066804